Kymera Therapeutics (NASDAQ:KYMR) reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune diseases. The company also said it expects to report phase IIb data for its STAT6 degrader, KT-621, in atopic dermatitis by year-end. Chief Executive Officer Nello Mainolfi said […]

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulatory submission later that year and a possible launch in early 2028. The company also reported progress in its Phase I program for STK-002, […]